Research digest
Ipamorelin is the first peptide engineered to release growth hormone — and almost nothing else.
Across rat, swine, and human studies it triggered a clean pulse of GH with minimal cortisol and prolactin. Here is the selectivity science, the open questions, and every quantitative claim cited.
The short version
Ipamorelin is a tiny lab-made peptide — a chain of just five building blocks — that tells the brain's hormone gland to release a quick burst of growth hormone (GH, the body's signal for repair and growth). What makes it stand out is what it does not do. Older peptides in its family also pushed up stress hormones like cortisol, and a milk-related hormone called prolactin. Ipamorelin mostly skips those, even at high doses. That clean, single-target action is its whole reputation.
In animal studies it released GH as strongly as the older peptides but stayed quiet on the side channels. In a small human study it produced one neat GH pulse and cleared the body in about two hours. The one larger human trial — for slow bowel recovery after surgery — did not work, and the peptide has never been approved as a medicine. People in research circles report better sleep and faster recovery, but also a warm facial flush after injecting; what people report — including the downsides — is on the effects page, and it is anecdotal, not proof.
What ipamorelin actually demonstrated
Ipamorelin released growth hormone in primary rat pituitary cells, anaesthetised rats, and conscious swine as potently as the older peptide GHRP-6 — the swine ED50 (the dose that produced half the maximum effect) was 2.3 nmol/kg for ipamorelin versus 3.9 nmol/kg for GHRP-6 [1]. The headline finding was selectivity: ipamorelin did not raise ACTH or cortisol (the body's main stress hormone) above the level seen with plain GHRH, even at doses more than 200 times its GH ED50 [1]. That single result is why it was named the first selective growth hormone secretagogue — a secretagogue being any compound that prompts a gland to secrete a hormone.
Ipamorelin works by switching on one specific receptor: GHS-R1a, the ghrelin receptor (the same docking site used by ghrelin, the body's natural 'hunger hormone'). When ipamorelin binds there on the pituitary's GH-producing cells, it sets off a calcium cascade inside the cell that pushes GH out [1]. The pathway it uses is separate from — and complementary to — the GHRH pathway, which is the entire reason researchers pair it with GHRH analogs such as CJC-1295 [12]. Curious how the binding works? Start with what does ipamorelin peptide do.
The human evidence — read honestly
Human data on ipamorelin is thin, and where it exists it is sobering. A population pharmacokinetic study in eight healthy male volunteers per dose level (five 15-minute intravenous infusions of 4.21 to 140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of roughly 2 hours, and a single discrete GH pulse peaking about 40 minutes after dosing [2]. That is the cleanest human snapshot of the molecule's behaviour.
The only published Phase 2 randomized controlled trial tells the harder story. In 114 adults recovering from bowel resection, ipamorelin at 0.03 mg/kg intravenously twice daily missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, which was not statistically significant (p=0.15) [3]. No specific safety alarm emerged in that short window, but the efficacy simply was not there. Ipamorelin has never been approved as a drug anywhere — a fact, not a footnote. The promise lives in the mechanism and the animal data; the clinical chapter remains unwritten. For the full picture of what people report and where the cautions lie, see Ipamorelin effects.
Why selectivity is the whole story
Most growth-hormone-releasing peptides are blunt instruments — they release GH but also stir cortisol, prolactin, and appetite. Ipamorelin was the proof-of-concept that you could decouple the GH pulse from those off-target hormones [1]. In a rat bone-growth study, subcutaneous ipamorelin at 18, 90, and 450 micrograms per day raised the longitudinal bone growth rate from 42 micrometers per day in vehicle controls to 44, 50, and 52 micrometers per day respectively — dose-dependently — with no measurable change in total IGF-1 or bone turnover markers [4], hinting that some of its skeletal effect is driven locally by the GH pulse itself.
The most recent published in-vivo work, a 2024 ferret study, found intraperitoneal ipamorelin (1 to 3 mg/kg) reduced cisplatin-induced body-weight loss by about 24% during the delayed phase, though it produced no anti-emetic effect [5]. The arc is consistent: a precise, selective tool with reproducible signals in animals, awaiting the human trials that would turn signal into verdict. Browse the full Ipamorelin research or jump to what is ipamorelin peptide.